These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 27737879)

  • 1. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
    Chao T; Furth EE; Vonderheide RH
    Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2
    Xie Y; Zhou T; Li X; Zhao K; Bai W; Hou X; Liu Z; Ni B; Zhang Z; Yan J; Wang Y; Jiang W; Wang H; Chang A; Gao S; Zhao T; Yang S; Huang C; Liu J; Hao J
    Gastroenterology; 2024 Jul; 167(2):281-297. PubMed ID: 38492894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
    Awaji M; Saxena S; Wu L; Prajapati DR; Purohit A; Varney ML; Kumar S; Rachagani S; Ly QP; Jain M; Batra SK; Singh RK
    FASEB J; 2020 Jul; 34(7):9405-9418. PubMed ID: 32453916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β.
    Jablonska J; Wu CF; Andzinski L; Leschner S; Weiss S
    Int J Cancer; 2014 Mar; 134(6):1346-58. PubMed ID: 24154944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis.
    Lesina M; Wörmann SM; Morton J; Diakopoulos KN; Korneeva O; Wimmer M; Einwächter H; Sperveslage J; Demir IE; Kehl T; Saur D; Sipos B; Heikenwälder M; Steiner JM; Wang TC; Sansom OJ; Schmid RM; Algül H
    J Clin Invest; 2016 Aug; 126(8):2919-32. PubMed ID: 27454298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
    Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
    Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.
    Li A; King J; Moro A; Sugi MD; Dawson DW; Kaplan J; Li G; Lu X; Strieter RM; Burdick M; Go VL; Reber HA; Eibl G; Hines OJ
    Am J Pathol; 2011 Mar; 178(3):1340-9. PubMed ID: 21356384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
    Luo H; Ikenaga N; Nakata K; Higashijima N; Zhong P; Kubo A; Wu C; Tsutsumi C; Shimada Y; Hayashi M; Oyama K; Date S; Abe T; Ideno N; Iwamoto C; Shindo K; Ohuchida K; Oda Y; Nakamura M
    J Exp Clin Cancer Res; 2024 Sep; 43(1):258. PubMed ID: 39261943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
    Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
    Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A microphysiological system reveals neutrophil contact-dependent attenuation of pancreatic tumor progression by CXCR2 inhibition-based immunotherapy.
    Shao S; Delk NA; Jones CN
    Sci Rep; 2024 Jun; 14(1):14142. PubMed ID: 38898176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice.
    Mei J; Liu Y; Dai N; Hoffmann C; Hudock KM; Zhang P; Guttentag SH; Kolls JK; Oliver PM; Bushman FD; Worthen GS
    J Clin Invest; 2012 Mar; 122(3):974-86. PubMed ID: 22326959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
    Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
    J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
    Cui D; Zhao Y; Xu J
    Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
    Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
    Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
    Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH
    Cancer Cell; 2012 Jun; 21(6):822-35. PubMed ID: 22698406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice.
    Hoffman MT; Kemp SB; Salas-Escabillas DJ; Zhang Y; Steele NG; The S; Long D; Benitz S; Yan W; Margolskee RF; Bednar F; Pasca di Magliano M; Wen HJ; Crawford HC
    Cell Mol Gastroenterol Hepatol; 2021; 11(2):349-369. PubMed ID: 32882403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Steele CW; Karim SA; Leach JDG; Bailey P; Upstill-Goddard R; Rishi L; Foth M; Bryson S; McDaid K; Wilson Z; Eberlein C; Candido JB; Clarke M; Nixon C; Connelly J; Jamieson N; Carter CR; Balkwill F; Chang DK; Evans TRJ; Strathdee D; Biankin AV; Nibbs RJB; Barry ST; Sansom OJ; Morton JP
    Cancer Cell; 2016 Jun; 29(6):832-845. PubMed ID: 27265504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.